The PARSC Trial, a Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Publication Name: ASCO 2011 Poster

Author(s): R. Salazar, R. Rosenberg, M. Lutke Holzik, J. Marshall4 , J. J. M. Van Der Hoeven, B. Glimelius, F. Bibeau, L. Stork-Sloots

Background: An 18-gene expression profile, ColoPrint, has been developed for identifying CC patients more likely to develop recurrent disease and who would be candidates for adjuvant chemotherapy. The gene signature was validated in in-silico datasets and independent patient cohorts of stage … Continued

Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients

Publication Name: ASCO GI 2011

Author(s): R. Rosenberg, M. Maak, U. Nitsche, T. Schuster, B. Kuenzli, I. Simon, R. Bender, K. P. Janssen and H. Friess

Background: Adjuvant therapy is not routinely recommended for stage II CC patients but may be considered for high-risk patients. In this study we aim to independently validate a genomic profile that was developed to identify high-risk patients and can assist in … Continued

Gene Signatures as predictors of response to neoadjuvant chemotherapy with docetaxel, doxorubicin, cyclophosphamide (TAC), or AC and nab-paclitaxel and carboplatin +/- trastuzumab in patients with stage II-III and inflammatory breast cancer.

Publication Name: ASCO Poster 2010

Author(s): G. Somlo, P. H. Frankel, L. Vora, S. Lau, T. H. Luu, L. Kruper, J. Yim, Y. Yen, F. de Snoo, R. A. Bender

Pathologic complete response (pCR) and residual cancer burden (RCB) scores of 0 (pCR) and 1 (near CR) after NCT predict for better survival (Symmans et al. J Clin Oncol 25:4414-22, 2007). Improved NCTs and molecular markers predicting for response are … Continued

Combining multigene profiling of molecular subtypes with the 70-gene profile for classification of breast cancer

Publication Name: Abstract, ASCO 2009

Author(s): Stork-Sloots L, Krijgsman O, Roepman P, et al. Combining multigene profiling of molecular subtypes with the 70-gene profile for classification of breast cancer. J Clin Oncol 2009; 27: 15s

Background: Classification of breast cancers into molecular subtypes may be important for accurate selection of therapy for patients. Herein we report a multigene profile for classification of breast cancer into molecular subtypes. The profile separates tumors into hormone receptor (HR)+/luminal-like, HER2+/ERBB2-like, … Continued

Microarray-based determination of ER, PR and HER2 receptor status: validation and comparison with IHC assessments

Publication Name: Poster, SABCS 2008

Author(s): Paul Roepman, Hugo Horlings, Oscar Krijgsman, Jolien Bueno-de-Mesquita, Richard Bender, Sabine Linn, Annuska Glas and Marc van de Vijver

In breast cancer patients the level of expression of estrogen receptor (ER), progesterone receptor (PR) and HER2 is predictive for prognosis and/or treatment response. However, differences in assessment methods and interpretation can substantially affect the accuracy and reproducibility of the … Continued

Feasibility of using core-needle biopsies for the 70-gene prognosis signature

Publication Name: Poster

Author(s): J Mayordomo, A Modollel, C Rolfo, S Morales, A Glas, A Floore, E van Lienen, F de Snoo, L Stork-Sloots

A 70-gene microarray prognosis signature was previously discovered to improve the selection of patients with breast cancer for adjuvant therapy.(1,2) This diagnostic test known as “MammaPrint” was recently validated in an independent cohort and implementation was shown to be feasible … Continued

MammaPrint accurately identifies good prognosis group within clinically indeterminate risk patients.

Publication Name: Poster, ESMO 2008

Author(s): A. M. Glas , F. de Snoo, C. Dreezen, P. Roepman, R. Bender, L. Van ‘t Veer .

A 70-gene tumor expression profile was established as a powerful predictor of disease outcome in patients with breast cancer.(1,2) The test, known as “MammaPrint,” was validated in independent cohorts, and implementation was shown to be feasible in community hospitals.(3-7) We … Continued

Analysis of the MammaPrint breast cancer assay in an older US General Hospital population.

Publication Name: Poster, AACR 2007

Author(s): Ben S. Wittner, Dennis C. Sgroi, Paula D. Ryan, Tako J. Bruinsma, Annuska M. Glas,

Breast cancer patients with similar pathological staging can have markedly different rates of disease-free and overall survival. A key challenge in breast cancer management is to accurately determine a patient’s risk of developing distant metastasis at the time of primary … Continued